Any assertion to the contrary is not supported by evidence It IS fair to say that there is no clear evidence of harm in a relatively data free zone in humans, and that there is a plausible argument for benefit based upon in vitro and animal studies as well as mechanism of action - particularly with BPC
Neurological symptoms often develop gradually and may include: Paraesthesia : tingling or 'pins and needles' sensations, typically starting in the feet and hands Numbness : reduced sensation in the extremities, which may affect balance and coordination Burning pain : particularly in the feet, often worse at night Weakness : muscle weakness and difficulty walking Balance problems : unsteady gait and increased fall risk due to proprioceptive impairment Cognitive changes : memory problems, confusion, difficulty concentrating, and mood disturbances Haematological signs may accompany neurological symptoms and include fatigue, weakness, pallor, and shortness of breath due to megaloblastic anaemia
click on the link on the left of the page titled Annual Policy Files and then select the relevant year to download the statewide CCRs and upper limits in the Downloads section of the web page
A reduction in the "burning" sensation is a common early marker in subject logs
Nothing here recommends, endorses, or instructs human use of DSIP, and the doses described are reported solely as a record of what was administered in published research settings
Use of compounded medications involves potential risks and should be discussed with a qualified healthcare provider
